Rezolute is trading 5.01% down now at $4.46, alongside a 4.24% drop in biotechnology stocks and losses across major U.S. indexes, suggesting sector and broader risk-off pressure are the most likely drivers.
- No fresh company-specific announcement or clinical update surfaced for September 1, 2026.
- Recent Rezolute coverage primarily references earlier FDA and clinical developments, not a new catalyst today.